| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
530233 Stock Overview
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India.
Auro Laboratories Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹96.95 |
| 52 Week High | ₹195.00 |
| 52 Week Low | ₹87.00 |
| Beta | 1 |
| 1 Month Change | -12.22% |
| 3 Month Change | -2.17% |
| 1 Year Change | -8.24% |
| 3 Year Change | 58.03% |
| 5 Year Change | 131.38% |
| Change since IPO | 4,606.31% |
Recent News & Updates
Shareholder Returns
| 530233 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.1% | -1.6% | -3.2% |
| 1Y | -8.2% | -11.0% | 9.0% |
Return vs Industry: 530233 exceeded the Indian Pharmaceuticals industry which returned -11% over the past year.
Return vs Market: 530233 underperformed the Indian Market which returned 9% over the past year.
Price Volatility
| 530233 volatility | |
|---|---|
| 530233 Average Weekly Movement | 6.0% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.7% |
Stable Share Price: 530233 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 530233's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Sharat Deorah | https://www.aurolabs.com |
Auro Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India. It offers APIs for various drugs, such as antihistamine, muscle relaxant, diuretic, iron deficiency, anti-diabetic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, and anti-inflammatory, as well as for other products, including potassium iodide, sodium iodide, and microcrystalline cellulose. The company also provides specialty chemicals comprising guanidine nitrate; dimethyl amine HCl; 2-ethoxy benzoic acid; and 3,4,5 - trimethoxy benzoic acid.
Auro Laboratories Fundamentals Summary
| 530233 fundamental statistics | |
|---|---|
| Market Cap | ₹604.24m |
| Earnings (TTM) | ₹38.96m |
| Revenue (TTM) | ₹465.47m |
15.5x
P/E Ratio1.3x
P/S RatioIs 530233 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 530233 income statement (TTM) | |
|---|---|
| Revenue | ₹465.47m |
| Cost of Revenue | ₹267.46m |
| Gross Profit | ₹198.01m |
| Other Expenses | ₹159.05m |
| Earnings | ₹38.96m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.25 |
| Gross Margin | 42.54% |
| Net Profit Margin | 8.37% |
| Debt/Equity Ratio | 25.6% |
How did 530233 perform over the long term?
See historical performance and comparisonValuation
Is Auro Laboratories undervalued compared to its fair value and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 530233 (₹96.95) is trading below our estimate of fair value (₹293.64)
Significantly Below Fair Value: 530233 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 530233 is good value based on its PE Ratio (15.5x) compared to the Indian Pharmaceuticals industry average (21.1x).
PE vs Market: 530233 is good value based on its PE Ratio (15.5x) compared to the Indian market (20.1x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 530233's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 530233 is good value based on its PB Ratio (2x) compared to the IN Pharmaceuticals industry average (2.5x).
Future Growth
How is Auro Laboratories forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
19.9%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Auro Laboratories has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Auro Laboratories performed over the past 5 years?
Past Performance Score
2/6Past Performance Score 2/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
22.5%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 530233 has high quality earnings.
Growing Profit Margin: 530233's current net profit margins (8.4%) are lower than last year (12.3%).
Past Earnings Growth Analysis
Earnings Trend: 530233's earnings have grown significantly by 22.5% per year over the past 5 years.
Accelerating Growth: 530233's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 530233 had negative earnings growth (-36.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.4%).
Return on Equity
High ROE: 530233's Return on Equity (12.9%) is considered low.
Financial Health
How is Auro Laboratories's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage
Financial Position Analysis
Short Term Liabilities: 530233's short term assets (₹337.0M) exceed its short term liabilities (₹80.3M).
Long Term Liabilities: 530233's short term assets (₹337.0M) exceed its long term liabilities (₹94.3M).
Debt to Equity History and Analysis
Debt Level: 530233 has more cash than its total debt.
Reducing Debt: 530233's debt to equity ratio has reduced from 133.3% to 25.6% over the past 5 years.
Debt Coverage: 530233's debt is well covered by operating cash flow (112.5%).
Interest Coverage: 530233's interest payments on its debt are well covered by EBIT (16.1x coverage).
Balance Sheet
Dividend
What is Auro Laboratories's current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 530233's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 530233's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 530233's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 530233's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as 530233 has not reported any payouts.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
15.5yrs
Average board tenure
CEO
Sharat Deorah (71 yo)
no data
Tenure
₹12,000,000
Compensation
Mr. Sharat Sahadeolal Deorah, B.Com. serves as the Managing Director and Executive Chairman of the Board at Auro Laboratories Limited. He serves as Director since May 26, 1989 at Auro Laboratories Limited.
CEO Compensation Analysis
Compensation vs Market: Sharat's total compensation ($USD154.15K) is above average for companies of similar size in the Indian market ($USD38.73K).
Compensation vs Earnings: Sharat's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Board Members
Experienced Board: 530233's board of directors are seasoned and experienced ( 15.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Auro Laboratories Limited's employee growth, exchange listings and data sources
Key Information
- Name: Auro Laboratories Limited
- Ticker: 530233
- Exchange: BSE
- Founded: 1989
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: ₹604.241m
- Shares outstanding: 6.23m
- Website: https://www.aurolabs.com
Number of Employees
Location
- Auro Laboratories Limited
- 314, T.V. Industrial Estate
- 3rd Floor
- Mumbai
- Maharashtra
- 400030
- India
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/05/17 00:00 |
| End of Day Share Price | 2022/05/17 00:00 |
| Earnings | 2021/12/31 |
| Annual Earnings | 2021/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.